Recombinant Flt3 Ligand

Flt3 ligand stimulates progenitor cells in the bone marrow, resulting in an increase in DC in the peripheral blood when administered to normal subjects and to patients with metastatic cancer.72-74 This property of Flt3 ligand makes it a candidate for use as a vaccine augmentation strategy, making available an increased number of DC that could possibly respond and contribute to a tumor vaccine in vivo. Disis et al. recently reported the results of a clinical trial involving 10 patients with HER-2/neu-overexpressing breast or ovarian cancer.75 Patients were given Flt3 ligand subcutaneously daily for 14 days of 28-day cycles and received a HER-2/neu peptide-based vaccine on day 7 of each cycle. Patients were treated for up to 6 cycles. Clinical responses were not assessable, as 9 of the 10 patients had no evidence of disease. However anti-HER-2/neu T-cell responses were induced in most of the patients. The clinical effectiveness of this approach needs to be tested.

10 Ways To Fight Off Cancer

10 Ways To Fight Off Cancer

Learning About 10 Ways Fight Off Cancer Can Have Amazing Benefits For Your Life The Best Tips On How To Keep This Killer At Bay Discovering that you or a loved one has cancer can be utterly terrifying. All the same, once you comprehend the causes of cancer and learn how to reverse those causes, you or your loved one may have more than a fighting chance of beating out cancer.

Get My Free Ebook

Post a comment